Seattle, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immunohistochemistry market is estimated to be valued at US$ 1,463.69 million in 2022 and expected to exhibit a CAGR of 6.6 % over the forecast period (2022-2030).
Key Trends and Analysis of the Global Immunohistochemistry Market:
Key trends in market include launches and approvals of novel products, and collaborations, partnerships, mergers, and acquisitions among key players. These key trends are expected to aid in the immunohistochemistry market growth.
For instance, in January 2021, Diaceutics PLC, a company that offers diagnostic tracking, laboratory mapping, testing, and other services, announced a strategic partnership with Canadian Pathology Quality Assurance, a non-profit organization, in order to boost the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing
Moreover, in December 2021, BioGenex, a company that designs, develops and commercializes molecular pathology systems for tumor diagnosis, prognosis, precision medicine, and life science research, announced the launch of three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. These include CD8A, CD56, and CD163.
Key players operating in the global immunohistochemistry market are focusing on the investment in clinical trials and adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations in order to strengthen their presence in the global market. For instance, according to data published on clinicaltrials.gov in 2021, out of the total number of globally registered clinical trials, around 32% of the trials are registered in the U.S. Such high number of clinical studies is expected to drive the market growth during the forecast period.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4795
Key Market Takeaways:
Global immunohistochemistry market is expected to exhibit a CAGR of 6.6% over the forecast period, owing to new product launches. For instance, In January 2021, Roche, a healthcare company, launched the CE-IVD automated digital pathology algorithms, uPath HER2 Dual ISH image analysis and uPath HER 2 (4B5) image analysis for the diagnosis of breast cancer. The image analysis algorithms facilitate the quick determination of whether the tumors are positive for HER2 biomarkers.
Among product, the antibodies segment accounted for the largest market share in 2022, owing to a number of product launches. For instance, in August 2020, Biocare Medical LLC, an innovator in automated immunohistochemistry (IHC) instrumentation, announced the launch of TIGIT monoclonal antibody for immunohistochemical applications.
Competitive Landscape:
Key players operating in the global immunohistochemistry market include Merck, Rockland Immunochemicals, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technologies, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc., Eagle Bioscience, Inc., Bio-Techne, Diagnostic Biosystems, Inc., and BioGenex
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4795
Market Segmentation:
- Global Immunohistochemistry Market, By Product:
- Antibodies
- Consumables
- Equipment
- Global Immunohistochemistry Market, By Application:
- In Vitro Diagnostic Applications
- Research Applications
- Others
- Global Immunohistochemistry Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
- Global Immunohistochemistry Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- By Country
- North America
Related Market Intelligence Reports:
Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Cancer Diagnostics Market, By Test Type (Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others)), Imaging (Ultrasound, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others), Biopsy (Needle Biopsy, Endoscopic Biopsy, Bone Marrow Biopsy, Others), Liquid Biopsy Immunohistochemistry In Situ Hybridization), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
